HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, imatinib-resistant CML cells were shown to exhibit non-hypoxic upregulation of HIF1α and its target genes, resulting in upregulation of glycolytic processes, increased glucose uptake and lactate production (106).